Moreover, the disruption of NR2F6 resulted in tumor suppression and enhanced the effect of PD-L1 blockade in tumor therapy, suggesting that NR2F6 inhibitors may become a new type of immunotherapy that can overcome resistance to existing ICB treatment.186,187. Here, NR2F6 is linked to neoplasm.